SG11201811184UA - Lag -3 binding members - Google Patents
Lag -3 binding membersInfo
- Publication number
- SG11201811184UA SG11201811184UA SG11201811184UA SG11201811184UA SG11201811184UA SG 11201811184U A SG11201811184U A SG 11201811184UA SG 11201811184U A SG11201811184U A SG 11201811184UA SG 11201811184U A SG11201811184U A SG 11201811184UA SG 11201811184U A SG11201811184U A SG 11201811184UA
- Authority
- SG
- Singapore
- Prior art keywords
- eddeva
- babraham
- cambridgeshire
- cambridge
- international
- Prior art date
Links
- 230000027455 binding Effects 0.000 title abstract 3
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title abstract 2
- 230000009870 specific binding Effects 0.000 abstract 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 3
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 11111111111111111111111111111111101111111111H111111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/220555 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C07K 16/28 (2006.01) A61K 39/00 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61P 35/00 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/EP2017/065052 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 20 June 2017 (20.06.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/352,470 20 June 2016 (20.06.2016) US Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (71) Applicant: F-STAR BETA LIMITED [GB/GB]; Edde- va B920, Babraham Research Campus, Cambridge Cam- Published: bridgeshire CB22 3AT (GB). — with international search report (Art. 2 I (3)) (72) Inventors: TUNA, Mihriban; c/o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cam- — bridge Cambridgeshire CB22 3AT (GB). WOLLERTON VAN HORCK, Francisca; c/o F-star Biotechnology Lim- ited, Eddeva B920, Babraham Research Campus, Cam- bridge Cambridgeshire CB22 3AT (GB). EVERETT, Katy = - Louise; c/o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge Cambridgeshire =_ CB22 3AT (GB). GASPAR, Miguel; c/o F-star Biotech- - nology Limited, Eddeva B920, Babraham Research Cam- = _ pus, Cambridge Cambridgeshire CB22 3AT (GB). KRA- = _ MAN, Matthew; c/o F-star Biotechnology Limited, Edde- va B920, Babraham Research Campus, Cambridge Cam- bridgeshire CB22 3AT (GB). KMIECIK, Katarzyna; c/ = _ o F-star Biotechnology Limited, Eddeva B920, Babraham = Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). FOSH, Natalie; c/o F-star Biotechnology Limited, = = = Eddeva B920, Babraham Research Campus, Cambridge = Cambridgeshire CB22 3AT (GB). = = (74) Agent: KEIRSTEAD, Tanis et al.; Mewburn Ellis LLP, = City Tower, 40 Basinghall Street, London, Greater London = EC2V 5DE (GB). = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = _ 1-1 in kr) kr) 0 ei ! (54) Title: LAG -3 BINDING MEMBERS IN (57) : The present invention relates to specific binding members which bind to lymphocyte- activation gene 3 (LAG-3). The 0 specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops \" of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in 0 cancer therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352470P | 2016-06-20 | 2016-06-20 | |
PCT/EP2017/065052 WO2017220555A1 (en) | 2016-06-20 | 2017-06-20 | Lag -3 binding members |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811184UA true SG11201811184UA (en) | 2019-01-30 |
Family
ID=59269995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811184UA SG11201811184UA (en) | 2016-06-20 | 2017-06-20 | Lag -3 binding members |
Country Status (14)
Country | Link |
---|---|
US (2) | US11214618B2 (en) |
EP (1) | EP3472206A1 (en) |
JP (2) | JP7085708B2 (en) |
KR (1) | KR20190022632A (en) |
CN (1) | CN109311993B (en) |
AU (1) | AU2017281157A1 (en) |
BR (1) | BR112018076525A2 (en) |
CA (1) | CA3027302A1 (en) |
IL (1) | IL263715A (en) |
MX (1) | MX2018016344A (en) |
RU (1) | RU2018142573A (en) |
SG (1) | SG11201811184UA (en) |
TW (1) | TW201831513A (en) |
WO (1) | WO2017220555A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109311993B (en) | 2016-06-20 | 2022-12-20 | F-星治疗有限公司 | LAG-3 binding elements |
SG11201811064TA (en) | 2016-06-20 | 2019-01-30 | F Star Delta Ltd | Binding molecules binding pd-l1 and lag-3 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
KR20200010500A (en) | 2017-05-30 | 2020-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | A composition comprising a combination of anti-LAG-3 antibodies, PD-1 pathway inhibitors, and immunotherapy agents |
EP3631454B1 (en) | 2017-05-30 | 2023-09-13 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
MX2019012076A (en) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody. |
AU2018387741A1 (en) | 2017-12-19 | 2020-07-23 | F-Star Therapeutics Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
JP2021532143A (en) | 2018-07-26 | 2021-11-25 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | LAG-3 combination therapy for the treatment of cancer |
CA3117016A1 (en) | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
KR20220016155A (en) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy |
EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
KR20220016157A (en) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | Cell localization signatures and combination therapies |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
KR20220066334A (en) | 2019-09-22 | 2022-05-24 | 브리스톨-마이어스 스큅 컴퍼니 | Quantitative spatial profiling for LAG-3 antagonist therapy |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
JP2023514152A (en) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | IL-10 and its uses |
IL298993A (en) | 2020-07-07 | 2023-02-01 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
MX2023002332A (en) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Lag-3 antagonist therapy for hepatocellular carcinoma. |
JP2023538955A (en) | 2020-08-31 | 2023-09-12 | ブリストル-マイヤーズ スクイブ カンパニー | Cellular localization signatures and immunotherapy |
EP4232019A1 (en) | 2020-10-23 | 2023-08-30 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
CA3201348A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Antibody compositions and methods of use thereof |
KR20240005700A (en) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy |
WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
CA3224890A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
CN114807054B (en) * | 2022-06-24 | 2022-09-13 | 北京索莱宝科技有限公司 | Mouse anti-human IgG monoclonal antibody hybridoma cell strain, antibody composition and kit |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2245404C3 (en) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Ground resistance, especially for spark plugs, and methods of manufacturing the same |
JPS531908B2 (en) | 1973-11-12 | 1978-01-23 | ||
JPS5746634B2 (en) | 1974-05-10 | 1982-10-04 | ||
JPS5146628A (en) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | TEIKOIRISUPAAKUPURAGU |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE19818214A1 (en) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Spark plug for combustion engine |
JP4578025B2 (en) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | Spark plug |
DK1772465T3 (en) | 2005-01-05 | 2009-05-25 | F Star Biotech Forsch & Entw | Synthetic immunoglobulin domains with modified binding properties in regions of the molecule that are not complementarity determining regions |
CN101248089A (en) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
EP2013348A4 (en) | 2006-03-30 | 2009-09-02 | Univ California | Methods and compositions for localized secretion of anti-ctla-4 antibodies |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
JP5276742B1 (en) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | Spark plug |
US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
TWI777174B (en) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | Antibody molecules to lag-3 and uses thereof |
JP5902757B2 (en) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | Spark plug |
WO2015198312A1 (en) | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
JP6665160B2 (en) | 2014-08-10 | 2020-03-13 | フェデラル−モーグル・イグニション・リミテッド・ライアビリティ・カンパニーFederal−Mogul Ignition Llc | Spark plug with improved seal |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
JP6783797B2 (en) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Anti-cancer fusion polypeptide |
MX2017014699A (en) | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Novel polypeptides. |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
JP6025921B1 (en) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | Spark plug |
CN108348573A (en) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | The novel protein of LAG-3 specificity |
EP3325009A4 (en) | 2015-07-22 | 2018-12-05 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
RU2018107991A (en) | 2015-08-07 | 2019-09-09 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | NEW FUSION POLYPEPTIDE SPECIFIC FOR LAG-3 AND PD-1 |
KR101782487B1 (en) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | Novel Antibody Binding to Mesothelin(MSLN), and Composition Comprising the Same |
TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
TWI754621B (en) | 2015-11-18 | 2022-02-11 | 美商默沙東藥廠 | Pd1 and/or lag3 binders |
WO2017087901A2 (en) | 2015-11-19 | 2017-05-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
US10501551B2 (en) | 2016-01-11 | 2019-12-10 | Inhibrx, Inc. | Multivalent and multispecific 41BB-binding fusion proteins |
DK3445788T3 (en) | 2016-04-22 | 2022-04-11 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CN109311993B (en) | 2016-06-20 | 2022-12-20 | F-星治疗有限公司 | LAG-3 binding elements |
TWI784957B (en) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | Immunocytokines |
SG11201811064TA (en) | 2016-06-20 | 2019-01-30 | F Star Delta Ltd | Binding molecules binding pd-l1 and lag-3 |
GB201612520D0 (en) * | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
KR20190031299A (en) | 2016-07-20 | 2019-03-25 | 주식회사 에스티큐브 | Methods of treating cancer using a combination of antibodies that bind to glycosylated PD-L1 |
EA201990578A1 (en) | 2016-09-23 | 2019-10-31 | BINDING MOLECULES THAT MODULATE THE CELL BIOLOGICAL ACTIVITY | |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
AU2018309339A1 (en) | 2017-08-04 | 2020-02-20 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
AU2018387741A1 (en) | 2017-12-19 | 2020-07-23 | F-Star Therapeutics Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
-
2017
- 2017-06-20 CN CN201780038556.1A patent/CN109311993B/en active Active
- 2017-06-20 KR KR1020197001120A patent/KR20190022632A/en unknown
- 2017-06-20 RU RU2018142573A patent/RU2018142573A/en not_active Application Discontinuation
- 2017-06-20 EP EP17734668.1A patent/EP3472206A1/en active Pending
- 2017-06-20 BR BR112018076525-2A patent/BR112018076525A2/en not_active Application Discontinuation
- 2017-06-20 WO PCT/EP2017/065052 patent/WO2017220555A1/en unknown
- 2017-06-20 JP JP2019518145A patent/JP7085708B2/en active Active
- 2017-06-20 MX MX2018016344A patent/MX2018016344A/en unknown
- 2017-06-20 CA CA3027302A patent/CA3027302A1/en active Pending
- 2017-06-20 AU AU2017281157A patent/AU2017281157A1/en active Pending
- 2017-06-20 US US16/311,596 patent/US11214618B2/en active Active
- 2017-06-20 SG SG11201811184UA patent/SG11201811184UA/en unknown
- 2017-06-20 TW TW106120621A patent/TW201831513A/en unknown
-
2018
- 2018-12-16 IL IL263715A patent/IL263715A/en unknown
-
2021
- 2021-11-23 US US17/534,315 patent/US20220185890A1/en active Pending
-
2022
- 2022-03-28 JP JP2022051878A patent/JP7394162B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3472206A1 (en) | 2019-04-24 |
JP2022089856A (en) | 2022-06-16 |
TW201831513A (en) | 2018-09-01 |
CA3027302A1 (en) | 2017-12-28 |
JP2019522490A (en) | 2019-08-15 |
JP7394162B2 (en) | 2023-12-07 |
CN109311993A (en) | 2019-02-05 |
MX2018016344A (en) | 2019-05-30 |
JP7085708B2 (en) | 2022-06-17 |
RU2018142573A (en) | 2020-07-21 |
IL263715A (en) | 2019-01-31 |
US11214618B2 (en) | 2022-01-04 |
BR112018076525A2 (en) | 2019-04-02 |
KR20190022632A (en) | 2019-03-06 |
CN109311993B (en) | 2022-12-20 |
WO2017220555A1 (en) | 2017-12-28 |
US20190330344A1 (en) | 2019-10-31 |
US20220185890A1 (en) | 2022-06-16 |
AU2017281157A1 (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811184UA (en) | Lag -3 binding members | |
SG11201811064TA (en) | Binding molecules binding pd-l1 and lag-3 | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201909777YA (en) | Modulatory polynucleotides | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201908171TA (en) | Compounds and compositions for treating hematological disorders | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201900634VA (en) | Chimeric antigen receptor | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201908472VA (en) | Compositions and methods for activating nk cells | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |